Quarterly report pursuant to Section 13 or 15(d)

Royalty Purchase Agreements - Viracta (Details)

v3.21.2
Royalty Purchase Agreements - Viracta (Details)
$ in Thousands
9 Months Ended 12 Months Ended
Mar. 22, 2021
USD ($)
item
Sep. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
Agreements      
Payments to acquire milestones and royalties   $ 20,500  
Long-term royalty receivables   55,075 $ 34,575
Impairment of long-term royalty receivable   0 $ 0
Viracta | Royalty Purchase Agreement [Member]      
Agreements      
Number of drug candidates | item 2    
Maximum amount of potential milestones and other payments receivable $ 54,000    
Amount of maximum consideration retained 20,000    
Maximum amount of potential regulatory and commercial milestones receivable 57,000    
Payments to acquire milestones and royalties 13,500    
Long-term royalty receivables $ 13,500    
Impairment of long-term royalty receivable   $ 0